Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Cantargia AB (CANTA)

Stockholm
Currency in SEK
Disclaimer
3.49
+0.42(+13.53%)
Closed
Fair Value
Unlock Value
Day's Range
3.103.49
52 wk Range
2.567.88
Bid/Ask
3.49 / 3.49
Prev. Close
3.07
Open
3.16
Day's Range
3.1-3.49
52 wk Range
2.56-7.88
Volume
469,923
Average Volume (3m)
388,361
1-Year Change
-53.48%
Shares Outstanding
183,686,684
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
12.67
Upside +263.04%

People Also Watch

128.08
NEWAb
+1.96%
23.1000
EMBRACb
+12.96%
How do you feel today about CANTA?
Vote to see community's results!
or

Cantargia AB Company Profile

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04 (Nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer and non-small cell lung cancer, as well as Phase Ib/II for the treatment of triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It is also developing CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V. and BioWa Inc. for the manufacture and production of CAN04; Allucent for the clinical study of CAN04; and Pancreatic Cancer Action Network, as well as GEICAM, Spanish breast cancer group. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.